Our Background

 

 






                                                                                                                                                                Isolation of human gut bacteria with specific properties                                                                   (i.e. immune stimulatory and specific binding properties)

 


Isolation of strains expressing specific carbohydrate antigens



In vitro and In vivo evaluation of probiotic properties



Safety assessment including toxicological studies

 


Risk assessment and risk group downgrading of bacteria species, e.g. Bacteroides xylanisolvens


                                                                                                                                              

Obtaining Novel Food Status (EU) and GRAS Status (US) for a new Microorganism (DSM  23964) 



Running probiotic specific Human Clinical Studies

 


Development of production processes from the lab to industrial scale